Investments
43Portfolio Exits
17About GeneChem Management
GeneChem Management Inc. is a Montreal, Canada-based stage agnostic private equity and venture capital firm that engages in everything from seed and startup financings to later stage mezzanine rounds to PIPE (private placements in public equities) investments. GeneChem customarily invests in the genomics industries with a focus on companies involved in gene discovery, functional genomics, bioinformatics, proteomics, and gene therapy amongst other related areas. Geographically, GeneChem seeks to invest in Canada, the United States, and Europe and generally prefers to have a Board seat and be the lead investor. In early stage deals, GeneChem may be the sole investor but it generally prefers to be part of syndicated deals as a lead or follower.
Want to inform investors similar to GeneChem Management about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest GeneChem Management News
Aug 17, 2013
Apple Giovanni Ferrara from Burrill & Company is a member of FundingPost online! Venture Fund Member Profile Share This Profile: Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $500 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. Giovanni Ferrara Managing Director Burrill & Company Prior to joining Burrill & Company, Mr. Ferrara was Manager at GeneChem Management, Inc., a healthcare venture capital firm, where he led several syndicated investments in Canada and the United States. He also held interim operating positions in portfolio companies and worked closely with BioChem Pharma's CSO and business development team in sourcing and pursuing inlicensing opportunities, which led to two of BioChem's largest deals, having achieved approximately $95 million in business development transactions. Prior to joining the venture capital community, he was a financial analyst at Letko, Brosseau & Associates. He began his career in healthcare as a pharmacist at a private cancer treatment center in Toronto focusing on experimental therapies. Representative Investments Adlyfe is a company that is developing screening and diagnostic products based upon its misfolded-protein detection (MPD) platform. The Company is developing its MPD Platform technology to produce simple, highly sensitive, low-cost and rapid-action test kits for the blood screening, human diagnostics and animal testing markets. The Company is currently working on the following programs: TSE-Pronucleon, to enable rapid and accurate testing of human blood units for vCJD and AD-Pronucleon an MPD Platform-based assay for early diagnosis of Alzheimers disease (AD). CardioKine develops pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications. Their initial product, Lixivaptan, an electrolyte-sparing diuretic, was licensed from Wyeth. Corazonas offers snacks that are formulated using ingredients that are scientifically proven to help maintain heart health. The first offering in the Corazonas platform is heart healthy tortilla chips, formulated using whole oats and plant sterols, with no trans fats, reduced sodium and virtually no saturated fat. Dreamerz has developed an all natural sleep aid beverage. Dreamerz beverage contains based product targeted to the quality of sleep market. About FundingPost For over Fourteen Years FundingPost has worked with thousandsof Angel and Venture Capital Investors. We believe that it isimportant to reach investors in every medium possible -both online and offline. We have been directly responsible fortons of success stories and Millions and Millions of dollars raised.We look forward to introducing your company to the leading Venture and Angel Investors nationwide. Sign up now: Entrepreneurs / Investors Join the FundingPost email list and learn how, when and where you can meet these Investors: Other Venture Profiles:
GeneChem Management Investments
43 Investments
GeneChem Management has made 43 investments. Their latest investment was in NuChem Therapeutics as part of their Unattributed VC on December 12, 2011.
GeneChem Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/4/2011 | Unattributed VC | NuChem Therapeutics | Yes | 2 | ||
6/21/2011 | Series D - II | Ambit Biosciences | $30M | No | ||
4/19/2010 | Series A - II | Sonexa Therapeutics | $7.23M | No | ||
5/21/2009 | Unattributed | |||||
5/8/2008 | Series A |
Date | 12/4/2011 | 6/21/2011 | 4/19/2010 | 5/21/2009 | 5/8/2008 |
|---|---|---|---|---|---|
Round | Unattributed VC | Series D - II | Series A - II | Unattributed | Series A |
Company | NuChem Therapeutics | Ambit Biosciences | Sonexa Therapeutics | ||
Amount | $30M | $7.23M | |||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 2 |
GeneChem Management Portfolio Exits
17 Portfolio Exits
GeneChem Management has 17 portfolio exits. Their latest portfolio exit was NuChem Therapeutics on February 22, 2019.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
2/22/2019 | Management Buyout | Management Buyout (MBO) | 1 | ||
7/15/2013 | Reverse Merger | 1 | |||
5/16/2013 | IPO | Public | 2 | ||
Date | 2/22/2019 | 7/15/2013 | 5/16/2013 | ||
|---|---|---|---|---|---|
Exit | Management Buyout | Reverse Merger | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Management Buyout (MBO) | Public | |||
Sources | 1 | 1 | 2 |
GeneChem Management Team
1 Team Member
GeneChem Management has 1 team member, including current President, Louis P. Lacasse.
Name | Work History | Title | Status |
|---|---|---|---|
Louis P. Lacasse | President | Current |
Name | Louis P. Lacasse |
|---|---|
Work History | |
Title | President |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.